Founded in Durham, United States, Parion Sciences is a development stage company focused on pioneering research and development in healthcare. The company's core mission is to restore the innate mucosal surface defense of the lung through innovative therapies. Parion's product pipeline includes ENaC pulmonary treatments, tPAD, and mucolytic agents, all targeting respiratory diseases caused by defective mucosal host defense mechanisms.
Parion Sciences has established notable partnerships and affiliations with leading research institutions and pharmaceutical companies. The company has achieved significant milestones in advancing its clinical trials and developing its therapeutic technologies. With a strong focus on respiratory health, Parion Sciences has made a substantial impact in the field of mucosal defense, contributing to improved treatment options for patients with chronic respiratory conditions.
